Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients

Liver Transplantation

Volumn 13, Issue 5, 2007, Pages 658-664

  Morard, Isabelle ^a   Dumortier, Jérôme ^a,b   Spahr, Laurent ^a   Hadengue, Antoine ^a   Majno, Pietro ^a   Morel, Philippe ^a   Mentha, Gilles ^a   Giostra, Emilliano ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; THYROTROPIN;

ADULT; AGED; ALBUMINURIA; ALCOHOL LIVER DISEASE; ANEMIA; ANKLE EDEMA; ARTHRALGIA; ARTICLE; BRAIN DISEASE; CENTRAL PONTINE MYELINOLYSIS; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DERMATITIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG DISEASE; MALE; MOUTH ULCER; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR;

AGED; CALCINEURIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; POSTOPERATIVE CARE; RETREATMENT; SIROLIMUS; TREATMENT OUTCOME;

EID: 34249023920     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21116     Document Type: Article

References (42)

1. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003;35(Suppl):193S-200S.
2. Sindhi R, Seward J, Mazariegos G, Soltys K, Seward L, Smith A, et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant 2005;9:391-397.
3. Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004;8:362-366.
4. Markiewicz M, Kalicinski P, Teisseyre J, Ismail H, Kaminski A, Teisseyre M. Rapamycin in children after liver transplantation. Transplant Proc 2003;35:2284-2286.
5. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000;6:734-740.
6. Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002:16(Suppl 7):49-51.
7. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-1085.
8. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tschehessnigg KH. Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003;16:504-509.
9. Nair S, Eason J, Loss G. Sirolimus. monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003;9:126-129.
10. Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K, et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003;35:3029-3031.
11. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004;49:1029-1035.
12. Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg KH. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol 2005;5:133-136.
13. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003;35(Suppl):209S-216S.
14. Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg K. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 2004;18:642-646.
15. Forgacs B, Merhav HJ, Lappin J, Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005;37:1912-1914.
16. Guba. M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
17. Casadio, F, Croci S, D'Errico Grigioni A, Corti B, Grigioni WF, Landuzzi L, et al. Toward the definition of immunosuppressive regimens with antitumor activity. Transplant Proc 2005;37:2144-2147.
18. Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005;11:1420-1425.
19. Heffron TG, Smallwood GA, Davis L, Martinez E, Stieber AC. Sirolimus-based immunosuppressive [correction of immunosuppresivel protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002;34:1522-1523.
20. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78:264-268.
21. Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E. Strolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005;19:698-703.
22. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249-256.
23. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
24. Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball PM, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998;66:1616-1621.
25. Barkmarm A, Nashan B, Schmidt HH, Boker KH, Emmanouilidis N, Rosenau J, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000;69:1886-1890.
26. Morard I, Mentha G, Spahr L, Majno P, Hadengue A, Huber O, et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006;20:96-101.
27. Burdmann. EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003;23:465-476.
28. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004;10:1189-1194.
29. Moreno JM, Rubio E, Gomez A, Lopez-Monclus J, Herreros A, Revilla J, et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003;35:1874-1876.
30. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005;37:2614-2615.
31. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005;79:1575-1580.
32. Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-591.
33. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357:609-610.
34. Raimondo ML, Dagher L, Papatheodoridis, GV, Rolando N, Patch DW, Davidson BR, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003;75:186-190.
35. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003;35(Suppl):37S-51S.
36. Dittrich E, Schmaldienst S, Soleiman A, Horl VVH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004;17:215-220.
37. Marti HP, Frey FJ. Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 2005;20:13-15.
38. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-1203.
39. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003;35(Suppl):52S-57S.
40. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004;19:1288-1292.
41. Andres A, Toso C, Morel P, Demuylder-Mischler S, Bosco D, Baertschiger R, et al. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation. Transplant Proc 2005;37:1326-1327.
42. Neff GW, Montalbano M, Slapak-Green G, Berney T, Bejarano PA, Joshi A, et al. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 2003;9:477-483.